A-Ching Chao1, Ching-Kuan Liu2, Chih-Hung Chen2, Huey-Juan Lin2, Chung-Hsiang Liu2, Jiann-Shing Jeng2, Chaur-Jong Hu2, Chih-Ping Chung2, Hung-Yi Hsu2, Wen-Yung Sheng2, Han-Hwa Hu1. 1. From the Graduate Institute of Clinical Medicine and Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (A.-C.C., C.-K.L.); Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan (A.-C.C., C.-K.L.); Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan (C.-H.C.); Department of Neurology, Chi-Mei Medical Center, Tainan, Taiwan (H.-J.L.); Department of Neurology, China Medical University Hospital, Taichung, Taiwan (C.-H.L.); Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan (J.-S.J.); Graduate Institute of Clinical Medicine and Department of Neurology, College of Medicine, Taipei Medical University, Taipei, Taiwan (C.-J.H., H.-H.H.); Department of Neurology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan (C.-P.C., W.-Y.S.); and Department of Neurology, Tungs' Taichung Metro Harbor Hospital and Department of Neurology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan (H.-Y.H.). achch@cc.kmu.edu.tw hanhwa@hotmail.com. 2. From the Graduate Institute of Clinical Medicine and Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (A.-C.C., C.-K.L.); Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan (A.-C.C., C.-K.L.); Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan (C.-H.C.); Department of Neurology, Chi-Mei Medical Center, Tainan, Taiwan (H.-J.L.); Department of Neurology, China Medical University Hospital, Taichung, Taiwan (C.-H.L.); Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan (J.-S.J.); Graduate Institute of Clinical Medicine and Department of Neurology, College of Medicine, Taipei Medical University, Taipei, Taiwan (C.-J.H., H.-H.H.); Department of Neurology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan (C.-P.C., W.-Y.S.); and Department of Neurology, Tungs' Taichung Metro Harbor Hospital and Department of Neurology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan (H.-Y.H.).
Abstract
BACKGROUND AND PURPOSE: The relationship between the dose of recombinant tissue-type plasminogen activator (r-tPA) and its safety/efficacy for ischemic stroke has not been well evaluated in the East Asian population. We assessed the safety/efficacy of different doses of r-tPA for acute ischemic stroke in Chinese patients. METHODS: A total of 1004 eligible patients were classified according to the dose of r-tPA received for managing acute ischemic stroke: 0.9 mg/kg (n=422), 0.8 mg/kg (n=202), 0.7 mg/kg (n=199), and 0.6 mg/kg (n=181). The safety outcome was symptomatic intracerebral hemorrhage and death within 3 months. The efficacy outcome was good functional outcome (modified Rankin Scale ≤1) at 3 months. RESULTS: There was a significant trend for symptomatic intracerebral hemorrhage with age (P=0.002). With multivariate logistic regression analysis, a dose of 0.9 mg/kg was a predictor of symptomatic intracerebral hemorrhage (P=0.0109), and a dose ≤0.65 mg/kg was a predictor of good functional outcome (P=0.0369). In patients aged 71 to 80 years, there was a significant trend of increasing symptomatic intracerebral hemorrhage (P=0.0130) and less good functional outcome (P=0.0179) with increasing doses of r-tPA. There was also a trend of increasing mortality (P=0.0971) at 3 months in these patients. CONCLUSIONS: These results did not support the dose of 0.9 mg/kg of r-tPA being optimal for all patients in the East Asian population. In elderly patients (71-80 years), a lower dose of 0.6 mg/kg is associated with a better outcome. Confirmation of the results through randomized trial is required.
BACKGROUND AND PURPOSE: The relationship between the dose of recombinant tissue-type plasminogen activator (r-tPA) and its safety/efficacy for ischemic stroke has not been well evaluated in the East Asian population. We assessed the safety/efficacy of different doses of r-tPA for acute ischemic stroke in Chinese patients. METHODS: A total of 1004 eligible patients were classified according to the dose of r-tPA received for managing acute ischemic stroke: 0.9 mg/kg (n=422), 0.8 mg/kg (n=202), 0.7 mg/kg (n=199), and 0.6 mg/kg (n=181). The safety outcome was symptomatic intracerebral hemorrhage and death within 3 months. The efficacy outcome was good functional outcome (modified Rankin Scale ≤1) at 3 months. RESULTS: There was a significant trend for symptomatic intracerebral hemorrhage with age (P=0.002). With multivariate logistic regression analysis, a dose of 0.9 mg/kg was a predictor of symptomatic intracerebral hemorrhage (P=0.0109), and a dose ≤0.65 mg/kg was a predictor of good functional outcome (P=0.0369). In patients aged 71 to 80 years, there was a significant trend of increasing symptomatic intracerebral hemorrhage (P=0.0130) and less good functional outcome (P=0.0179) with increasing doses of r-tPA. There was also a trend of increasing mortality (P=0.0971) at 3 months in these patients. CONCLUSIONS: These results did not support the dose of 0.9 mg/kg of r-tPA being optimal for all patients in the East Asian population. In elderly patients (71-80 years), a lower dose of 0.6 mg/kg is associated with a better outcome. Confirmation of the results through randomized trial is required.
Authors: Xia Wang; Thompson G Robinson; Tsong-Hai Lee; Qiang Li; Hisatomi Arima; Philip M Bath; Laurent Billot; Joseph Broderick; Andrew M Demchuk; Geoffrey Donnan; Jong S Kim; Pablo Lavados; Richard I Lindley; Sheila O Martins; Veronica V Olavarria; Jeyaraj D Pandian; Mark W Parsons; Octavio M Pontes-Neto; Stefano Ricci; Vijay K Sharma; Nguyen H Thang; Ji-Guang Wang; Mark Woodward; Craig S Anderson; John Chalmers Journal: JAMA Neurol Date: 2017-11-01 Impact factor: 18.302
Authors: Lily Song; Xia Wang; Thompson Robinson; Richard I Lindley; Hisatomi Arima; Pablo M Lavados; Xiaoying Chen; John Chalmers; Craig S Anderson Journal: Stroke Vasc Neurol Date: 2017-05-22